Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Yingke Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9632-2597; OpenAlex author ID A5034901751. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2021: 3 papers · 2022: 4 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 12

  1. HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer. Last author DOI 10.1016/j.molcel.2026.06.022↗
  2. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-26-0923↗
  3. E2F3 activates NF-κB signaling through TRIM26 mediated TAB1 ubiquitination in pancreatic cancer. Co-author DOI 10.7150/ijbs.127710↗
  4. BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. Last author DOI 10.7150/ijbs.104977↗
  5. Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. Co-author DOI 10.1016/j.bbadis.2024.167183↗
  6. ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215855↗
  7. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-21-4362↗
  8. CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. Co-author DOI 10.7150/ijbs.68995↗
  9. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
  10. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. Co-author DOI 10.1016/j.bbadis.2021.166213↗
  11. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. Co-author DOI 10.1038/s41419-021-04118-4↗
  12. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. First author DOI 10.1038/s41420-021-00462-8↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 12 shared papers, 2021–2026 · strength 2.20
  2. Dianyun Ren · 8 shared papers, 2021–2026 · strength 1.33
  3. Gengdu Qin · 7 shared papers, 2022–2026 · strength 1.31
  4. Haixin Yu · 5 shared papers, 2022–2026 · strength 0.89
  5. Xin Jin · 5 shared papers, 2021–2022 · strength 0.73
  6. Shanmiao Gou · 3 shared papers, 2025–2026 · strength 0.72
  7. Taoyu Chen · 3 shared papers, 2022–2026 · strength 0.62
  8. Yan Sun · 4 shared papers, 2021–2024 · strength 0.60
  9. Hongkun Cai · 2 shared papers, 2026 · strength 0.56
  10. Jingyuan Zhao · 3 shared papers, 2021–2024 · strength 0.45
  11. Yuhan Zhao · 2 shared papers, 2024–2025 · strength 0.41
  12. Penglin Pan · 3 shared papers, 2022 · strength 0.41
  13. Hongkun Cai · 2 shared papers, 2022–2024 · strength 0.33
  14. Feng Guo · 2 shared papers, 2021–2022 · strength 0.31
  15. Feng Guo · 1 shared paper, 2026 · strength 0.30
  16. Qiyue Zhang · 1 shared paper, 2026 · strength 0.30
  17. Jian Shen · 2 shared papers, 2021–2022 · strength 0.27
  18. Tao Yin · 1 shared paper, 2026 · strength 0.26
  19. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  20. Huan Zhang · 1 shared paper, 2022 · strength 0.15
  21. Chen Zhou · 1 shared paper, 2022 · strength 0.14
  22. Yan Ping Sun · 1 shared paper, 2021 · strength 0.14
  23. Chong Yang · 1 shared paper, 2021 · strength 0.14
  24. Yang Gao · 1 shared paper, 2021 · strength 0.14
  25. Ping Fan · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.